MX2018001557A - Reactivos quirales para la preparacion de oligomeros homogeneos. - Google Patents

Reactivos quirales para la preparacion de oligomeros homogeneos.

Info

Publication number
MX2018001557A
MX2018001557A MX2018001557A MX2018001557A MX2018001557A MX 2018001557 A MX2018001557 A MX 2018001557A MX 2018001557 A MX2018001557 A MX 2018001557A MX 2018001557 A MX2018001557 A MX 2018001557A MX 2018001557 A MX2018001557 A MX 2018001557A
Authority
MX
Mexico
Prior art keywords
preparation
chiral reagents
diastereomerically pure
oligomers
homogeneous oligomers
Prior art date
Application number
MX2018001557A
Other languages
English (en)
Inventor
Wook Choi Hyeong
Endo Atsushi
t yu Robert
Fang Francis
Shan Mingde
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2018001557A publication Critical patent/MX2018001557A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Proporcionamos fosforamidocloridato morfolino nucleósidos activados diastereoméricamente puros o sustancialmente diastereoméricamente puros, los métodos de su preparación y los métodos de su uso en el acoplamiento estereoespecífico para la síntesis estereoespecífica de oligómeros de morfolino fosforodiamidato (PMO) diastereoméricamente puros.
MX2018001557A 2015-08-05 2016-08-05 Reactivos quirales para la preparacion de oligomeros homogeneos. MX2018001557A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562201510P 2015-08-05 2015-08-05
PCT/US2016/045876 WO2017024264A2 (en) 2015-08-05 2016-08-05 Chiral reagents for preparation of homogeneous oligomers

Publications (1)

Publication Number Publication Date
MX2018001557A true MX2018001557A (es) 2018-05-02

Family

ID=56943909

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018001557A MX2018001557A (es) 2015-08-05 2016-08-05 Reactivos quirales para la preparacion de oligomeros homogeneos.
MX2022000124A MX2022000124A (es) 2015-08-05 2018-02-06 Reactivos quirales para la preparacion de oligomeros homogeneos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022000124A MX2022000124A (es) 2015-08-05 2018-02-06 Reactivos quirales para la preparacion de oligomeros homogeneos.

Country Status (31)

Country Link
US (3) US10457698B2 (es)
EP (2) EP4039690A1 (es)
JP (3) JP6978406B2 (es)
KR (1) KR20180044303A (es)
CN (3) CN113461733A (es)
AU (3) AU2016302009B2 (es)
BR (1) BR122023025447A2 (es)
CA (1) CA2994842A1 (es)
CL (1) CL2018000322A1 (es)
CO (1) CO2018001615A2 (es)
CY (1) CY1125552T1 (es)
DK (1) DK3331891T3 (es)
ES (1) ES2907629T3 (es)
HK (1) HK1248708A1 (es)
HR (1) HRP20220129T1 (es)
HU (1) HUE057593T2 (es)
IL (3) IL293066A (es)
LT (1) LT3331891T (es)
MA (1) MA44209B1 (es)
MD (1) MD3331891T2 (es)
MX (2) MX2018001557A (es)
MY (1) MY196627A (es)
PE (1) PE20180687A1 (es)
PH (1) PH12018500265A1 (es)
PL (1) PL3331891T3 (es)
PT (1) PT3331891T (es)
RS (1) RS62930B1 (es)
SI (1) SI3331891T1 (es)
UA (1) UA123995C2 (es)
WO (1) WO2017024264A2 (es)
ZA (2) ZA201801518B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122023025447A2 (pt) 2015-08-05 2024-01-16 Eisai R&D Management Co., Ltd. Composto substancialmente diastereomericamente puro, método para preparar um oligonucleotídeo e composição substancialmente diastereomericamente pura
JP2019534862A (ja) * 2016-09-20 2019-12-05 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト ホスホルアミダイト化学を使用する骨格修飾モルホリノオリゴヌクレオチド及びキメラの合成
JPWO2021132591A1 (es) 2019-12-26 2021-07-01
KR20220145865A (ko) 2020-02-28 2022-10-31 니뽄 신야쿠 가부시키가이샤 엑손 51의 스키핑을 유도하는 안티센스 핵산
CN117120456A (zh) 2020-12-11 2023-11-24 卫材R&D管理有限公司 聚-吗啉代寡核苷酸缺口体
US20220195437A1 (en) 2020-12-11 2022-06-23 Eisai R&D Management Co., Ltd. Tau-targeting oligonucleotide gapmers
JP2024518780A (ja) 2021-04-28 2024-05-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 神経変性障害の治療用アンチセンスオリゴヌクレオチド及びその使用
WO2024010870A2 (en) * 2022-07-07 2024-01-11 Eisai R&D Management Co., Ltd. Crystalline monomers for preparing antisense oligonucleotides and methods of their preparation and use
WO2024092256A2 (en) 2022-10-27 2024-05-02 Eisai R&D Management Co., Ltd. Peptide-antisense oligonucleotides and their use for treatment of neurodegenerative disorders

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185444A (en) * 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US6117993A (en) * 1995-05-23 2000-09-12 Hybridon, Inc. Synthons for oligonucleotide synthesis
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5874554A (en) * 1996-12-13 1999-02-23 Incyte Pharmaceuticals, Inc. Methods and solvent vehicles for reagent delivery in oligonucleotide synthesis using automated pulse jetting devices
US6306599B1 (en) * 1999-07-16 2001-10-23 Agilent Technologies Inc. Biopolymer arrays and their fabrication
US7135565B2 (en) * 2000-07-28 2006-11-14 Agilent Technologies, Inc. Synthesis of polynucleotides using combined oxidation/deprotection chemistry
AR036122A1 (es) 2001-07-03 2004-08-11 Avecia Biotechnology Inc Un complejo de sal que comprende un n-alquilimidazol y una 1,1-dioxo-1,2-dihidro-1l6-benzo [d]-isotiazol-3-ona y un metodo para sintetizar oligonucleotidos utilizando la quimica de fosforamidita
CN101861318A (zh) 2007-11-15 2010-10-13 Avi生物制药公司 合成吗啉代低聚物的方法
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
WO2011018798A2 (en) 2009-08-14 2011-02-17 Indian Association For The Cultivation Of Science Morpholino-based antisense agent
BR112012031363A2 (pt) * 2010-05-28 2021-10-26 Sarepta Therapeutcs, Inc Análogos de oligonucleotídeo tendo ligações intersubunidades modificadas e/ou grupos terminais.
EP2623507B1 (en) * 2010-09-30 2016-11-02 Nippon Shinyaku Co., Ltd. Morpholino nucleic acid derivative
EP2704749A1 (en) * 2011-05-05 2014-03-12 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
US9161948B2 (en) * 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
KR20200090975A (ko) 2011-10-07 2020-07-29 길리애드 사이언시즈, 인코포레이티드 항-바이러스 뉴클레오티드 유사체의 제조 방법
AU2012340390B2 (en) 2011-11-18 2016-11-24 Sarepta Therapeutics, Inc. Functionally-modified oligonucleotides and subunits thereof
US10066228B2 (en) 2011-11-30 2018-09-04 Sarepta Therapeutics, Inc. Oligonucleotides for treating expanded repeat diseases
CN102702265A (zh) * 2012-05-14 2012-10-03 天津特安化学科技有限公司 一种固相合成磷酰二胺吗啉代寡核苷酸及方法
BR122023025447A2 (pt) * 2015-08-05 2024-01-16 Eisai R&D Management Co., Ltd. Composto substancialmente diastereomericamente puro, método para preparar um oligonucleotídeo e composição substancialmente diastereomericamente pura
KR20180030917A (ko) 2015-08-05 2018-03-26 얀센 바이오테크 인코포레이티드 항-cd154 항체 및 그의 사용 방법
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
DE102015214943A1 (de) 2015-08-05 2017-02-09 Siemens Aktiengesellschaft Verfahren und Anlage für eine chemische Synthese

Also Published As

Publication number Publication date
US20210171555A1 (en) 2021-06-10
AU2021290235A1 (en) 2022-01-20
WO2017024264A3 (en) 2017-03-30
ZA201905394B (en) 2022-07-27
IL257353A (en) 2018-04-30
ES2907629T3 (es) 2022-04-25
US20200115405A1 (en) 2020-04-16
AU2023226763A1 (en) 2023-09-28
AU2016302009A1 (en) 2018-03-29
HRP20220129T1 (hr) 2022-04-15
KR20180044303A (ko) 2018-05-02
IL284611B1 (en) 2023-07-01
RS62930B1 (sr) 2022-03-31
IL257353B2 (en) 2023-02-01
IL284611B2 (en) 2023-11-01
JP6978406B2 (ja) 2021-12-08
US10836784B2 (en) 2020-11-17
US10457698B2 (en) 2019-10-29
MA44209B1 (fr) 2022-03-31
IL284611A (en) 2021-08-31
PL3331891T3 (pl) 2022-03-28
BR122023025447A2 (pt) 2024-01-16
MA44209A (fr) 2021-04-28
MD3331891T2 (ro) 2022-04-30
EP3331891A2 (en) 2018-06-13
RU2018107663A3 (es) 2020-05-21
CN113461733A (zh) 2021-10-01
CN117924364A (zh) 2024-04-26
PE20180687A1 (es) 2018-04-23
WO2017024264A2 (en) 2017-02-09
CL2018000322A1 (es) 2018-05-18
HUE057593T2 (hu) 2022-05-28
JP2023085402A (ja) 2023-06-20
PH12018500265A1 (en) 2018-08-13
IL293066A (en) 2022-07-01
SI3331891T1 (sl) 2022-04-29
LT3331891T (lt) 2022-02-25
AU2021290235B2 (en) 2023-06-08
MX2022000124A (es) 2022-02-16
EP4039690A1 (en) 2022-08-10
CN108350005B (zh) 2024-02-06
JP2022003067A (ja) 2022-01-11
EP3331891B1 (en) 2021-12-15
MY196627A (en) 2023-04-23
CA2994842A1 (en) 2017-02-09
PT3331891T (pt) 2022-02-28
BR112018002430A2 (pt) 2018-09-18
UA123995C2 (uk) 2021-07-07
HK1248708A1 (zh) 2018-10-19
JP7254869B2 (ja) 2023-04-10
US20180222932A1 (en) 2018-08-09
CO2018001615A2 (es) 2018-07-19
IL257353B (en) 2022-10-01
CY1125552T1 (el) 2024-02-16
RU2018107663A (ru) 2019-09-05
CN108350005A (zh) 2018-07-31
WO2017024264A8 (en) 2018-04-12
AU2016302009B2 (en) 2021-09-30
DK3331891T3 (da) 2022-02-28
ZA201801518B (en) 2020-10-28
JP2018525380A (ja) 2018-09-06

Similar Documents

Publication Publication Date Title
MX2022000124A (es) Reactivos quirales para la preparacion de oligomeros homogeneos.
MX2018015853A (es) Anticuerpos multiespecificos frente a los grupos de diferenciacion 40 y 137 (cd40 y cd137).
ZA201802657B (en) Crystal forms of beta-nicotinamide mononucleotide
AU2015329974A8 (en) GaINAc phosphoramidites, nucleic acid conjugates thereof and their use
EP3189367A4 (en) Systems, apparatus, and methods for using eyewear, or other wearable item, to confirm the identity of an individual
MX2016000997A (es) Metodos y composiciones para detectar contaminacion bacteriana.
BR112017007170A2 (pt) anticorpos anti-ox40 humanizados e suas utilizações
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
MX354267B (es) Nucléosidos, nucleótidos, y ácidos nucleicos modificados, y usos de los mismos.
MX2016007541A (es) Moléculas modificadas de ácido nucleico y usos de las mismas.
MX2016002571A (es) Regulador de ph de transduccion.
EP3331822A4 (en) SYNTHESIS AND PROCESSING OF Q-CARBON AND Q-BN AND DIRECT CONVERSION OF CARBON DIAMOND, BN AND C-BN
SG10201902326XA (en) Mk2 inhibitors and uses thereof
SG11201710665TA (en) Microorganisms for Producing Putrescine or Ornithine and Process for Producing Putrescine or Ornithine Using Them
BR112018012913A2 (pt) tratamento in situ de sementes em sulco
MX353307B (es) Proceso para la preparacion de inhibidores del cotransportador de glucosa dependiente de bencilbencen sodio 2 (sglt2).
MX2017004655A (es) Compuestos de hidroxil purinas y aplicaciones de estos.
MX2019013124A (es) Proteinas de fusion de inhibidor de tripsina urinaria (uti).
IN2014MU00455A (es)
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.
IL239333B (en) A system for creating, transmitting and receiving additional signals and the useful methods by the way
AU2016204389A1 (en) Kinase inhibitors for the treatment of cancer
EP3296393A4 (en) Method for producing culture containing megakaryocytes, and method for producing platelets using same
GB2550501A (en) Data filtering and mining using multiple-level, composite-attribute tree-node diagrams
IN2014DE00883A (es)